36 related articles for article (PubMed ID: 1313234)
1. Clinical pharmacokinetics of amifostine and WR1065 in pediatric patients with medulloblastoma.
McKibbin T; Panetta JC; Fouladi M; Gajjar A; Bai F; Okcu MF; Stewart CF
Clin Cancer Res; 2010 Feb; 16(3):1049-57. PubMed ID: 20103669
[TBL] [Abstract][Full Text] [Related]
2. Administration of amifostine in the stage of remission induction can benefit the patients with hematological malignancy in autologous stem cell transplantation: a retrospective study.
Wu M; Wu K; Chen P; Li P; Xie Y
Transl Cancer Res; 2020 Sep; 9(9):5147-5154. PubMed ID: 35117881
[TBL] [Abstract][Full Text] [Related]
3. Development of Second-Generation CDK2 Inhibitors for the Prevention of Cisplatin-Induced Hearing Loss.
Hazlitt RA; Teitz T; Bonga JD; Fang J; Diao S; Iconaru L; Yang L; Goktug AN; Currier DG; Chen T; Rankovic Z; Min J; Zuo J
J Med Chem; 2018 Sep; 61(17):7700-7709. PubMed ID: 30091915
[TBL] [Abstract][Full Text] [Related]
4. Progress in the Development of Preventative Drugs for Cisplatin-Induced Hearing Loss.
Hazlitt RA; Min J; Zuo J
J Med Chem; 2018 Jul; 61(13):5512-5524. PubMed ID: 29361217
[TBL] [Abstract][Full Text] [Related]
5. Cisplatin-Induced Ototoxicity: Effects, Mechanisms and Protection Strategies.
Callejo A; Sedó-Cabezón L; Juan ID; Llorens J
Toxics; 2015 Jul; 3(3):268-293. PubMed ID: 29051464
[TBL] [Abstract][Full Text] [Related]
6. Normal tissue radioprotection by amifostine via Warburg-type effects.
Koukourakis MI; Giatromanolaki A; Zois CE; Kalamida D; Pouliliou S; Karagounis IV; Yeh TL; Abboud MI; Claridge TD; Schofield CJ; Sivridis E; Simopoulos C; Tokmakidis SP; Harris AL
Sci Rep; 2016 Aug; 6():30986. PubMed ID: 27507219
[TBL] [Abstract][Full Text] [Related]
7. Radiation damage and radioprotectants: new concepts in the era of molecular medicine.
Koukourakis MI
Br J Radiol; 2012 Apr; 85(1012):313-30. PubMed ID: 22294702
[TBL] [Abstract][Full Text] [Related]
8. Protective effect of L-carnitine versus amifostine against cisplatin-induced nephrotoxicity in rats.
Uzunoglu S; Karagol H; Ozpuyan F; Cosar R; Cicin I; Yurutcaloglu V; Denizli B; Tanriverdi Ö; Sut N; Kocak Z
Med Oncol; 2011 Dec; 28 Suppl 1():S690-6. PubMed ID: 21140244
[TBL] [Abstract][Full Text] [Related]
9. Neuroprotection with amifostine in the first-line treatment of advanced ovarian cancer with carboplatin/paclitaxel-based chemotherapy--a double-blind, placebo-controlled, randomized phase II study from the Arbeitsgemeinschaft Gynäkologische Onkologoie (AGO) Ovarian Cancer Study Group.
Hilpert F; Stähle A; Tomé O; Burges A; Rossner D; Späthe K; Heilmann V; Richter B; du Bois A;
Support Care Cancer; 2005 Oct; 13(10):797-805. PubMed ID: 16025262
[TBL] [Abstract][Full Text] [Related]
10. Amifostine: an update on its clinical status as a cytoprotectant in patients with cancer receiving chemotherapy or radiotherapy and its potential therapeutic application in myelodysplastic syndrome.
Culy CR; Spencer CM
Drugs; 2001; 61(5):641-84. PubMed ID: 11368288
[TBL] [Abstract][Full Text] [Related]
11. In vitro protection from cisplatin-induced neurotoxicity by amifostine and its metabolite WR1065.
Verstappen CC; Geldof AA; Postma TJ; Heimans JJ
J Neurooncol; 1999 Aug; 44(1):1-5. PubMed ID: 10582662
[TBL] [Abstract][Full Text] [Related]
12. A risk-benefit assessment of amifostine in cytoprotection.
Mabro M; Faivre S; Raymond E
Drug Saf; 1999 Nov; 21(5):367-87. PubMed ID: 10554052
[TBL] [Abstract][Full Text] [Related]
13. Effects of amifostine on cisplatin induced DNA adduct formation and toxicity in malignant glioma and normal tissues in rat.
Bergström P; Johnsson A; Bergenheim T; Henriksson R
J Neurooncol; 1999 Mar; 42(1):13-21. PubMed ID: 10360475
[TBL] [Abstract][Full Text] [Related]
14. Clinical and preclinical modulation of chemotherapy-induced toxicity in patients with cancer.
Hoekman K; van der Vijgh WJ; Vermorken JB
Drugs; 1999 Feb; 57(2):133-55. PubMed ID: 10188757
[TBL] [Abstract][Full Text] [Related]
15. Amifostine. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential as a radioprotector and cytotoxic chemoprotector.
Spencer CM; Goa KL
Drugs; 1995 Dec; 50(6):1001-31. PubMed ID: 8612469
[TBL] [Abstract][Full Text] [Related]
16. WR2721 as a modulator of cisplatin- and carboplatin-induced side effects in comparison with other chemoprotective agents: a molecular approach.
Treskes M; van der Vijgh WJ
Cancer Chemother Pharmacol; 1993; 33(2):93-106. PubMed ID: 8261581
[TBL] [Abstract][Full Text] [Related]
17. Amifostine: potential for clinically useful cytoprotection.
Budd GT; Lorenzi V; Ganapathi R; Adelstein D; Pelley R; Olencki T; McLain D; Bukowski RM
Support Care Cancer; 1994 Nov; 2(6):380-4. PubMed ID: 7858931
[TBL] [Abstract][Full Text] [Related]
18. The reversal of cisplatin-protein interactions by the modulating agent WR2721 and its metabolites WR1065 and WR33278.
Treskes M; Holwerda U; Nijtmans LG; Pinedo HM; van der Vijgh WJ
Cancer Chemother Pharmacol; 1992; 29(6):467-70. PubMed ID: 1314713
[TBL] [Abstract][Full Text] [Related]
19. Effects of the modulating agent WR2721 and its main metabolites on the formation and stability of cisplatin-DNA adducts in vitro in comparison to the effects of thiosulphate and diethyldithiocarbamate.
Treskes M; Nijtmans LG; Fichtinger-Schepman AM; van der Vijgh WJ
Biochem Pharmacol; 1992 Mar; 43(5):1013-9. PubMed ID: 1313234
[TBL] [Abstract][Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
